alendronate has been researched along with prednisolone in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Simmons, DJ; Wimalawansa, SJ | 1 |
| Compston, JE | 1 |
| Bellido, T; Manolagas, SC; Parfitt, AM; Plotkin, LI; Roberson, PK; Weinstein, RS | 1 |
| Gündüz, OH; Ozoran, K; Uçan, H; Yilmaz, L; Yücel, M | 1 |
| Bellido, T; Chen, JR; Jilka, RL; Landes, RD; Manolagas, SC; Parfitt, AM; Powers, CC; Stewart, SA; Weinstein, RS | 1 |
| Okada, N | 1 |
| Akahoshi, S; Arita, S; Ikeda, S; Ito, M; Morishita, Y; Nakamura, T; Sakai, A; Shiraishi, A; Tsutsumi, H | 1 |
| Chakravarty, K; Hakim, A; Hughes, R; Keat, A; Kuttikat, A | 1 |
| Katayama, K; Matsuno, T | 1 |
| Kaneko, F; Nakamura, K; Oyama, N; Satoh, M; Yamada, H | 1 |
| Nakayamada, S; Nawata, M; Okada, Y; Saito, K; Tanaka, Y | 1 |
| Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nakahara, T; Saito, H; Sasaki, M; Tsujikawa, T | 1 |
| Funakawa, I; Funasaka, Y; Kaji, H; Kanda, F; Kuroki, Y; Murakawa, Y; Sugimoto, T | 1 |
| Tu, J; Von Nida, J | 1 |
| Bereket, A; Bozaykut, A; Guran, T; Paketçi, C; Seren, LP; Sezer, RG | 1 |
| Chan, YC; Chan, YH; Chua, SH; Koh, ET; Tan, SH; Tan, SS; Tee, SI; Tsou, IY; Yosipovitch, G | 1 |
| Albrecht, J; Werth, VP | 1 |
| Soen, S | 1 |
| Cho, KO; Choi, J; Oh, J; Park, S; Son, KY | 1 |
| Banfi, G; Congiu, T; Mariotti, M; Pasqualetti, S | 1 |
| Axelsson, KF; Lorentzon, M; Lundh, D; Nilsson, AG; Wedel, H | 1 |
| Inoue, T; Iseri, K; Iyoda, M; Matsumoto, K; Sanada, D; Shibata, T; Tachibana, S; Watanabe, M | 1 |
3 review(s) available for alendronate and prednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Measures for osteoporosis in the dermatological field--vitamin D3 and bisphosphonate].
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Bone Density; Cholecalciferol; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Lumbar Vertebrae; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Prednisolone; Skin Diseases | 2004 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Mice; Middle Aged; Osteogenesis; Osteoporosis; Practice Guidelines as Topic; Prednisolone; Risedronic Acid; Risk; Teriparatide | 2014 |
8 trial(s) available for alendronate and prednisolone
| Article | Year |
|---|---|
Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Osteoporosis; Prednisolone | 1999 |
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Calcium; Clinical Chemistry Tests; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Methotrexate; Middle Aged; Osteoporosis, Postmenopausal; Prednisolone; Treatment Outcome | 2001 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Family Practice; Female; Fractures, Bone; Humans; Incidence; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis, Postmenopausal; Prednisolone; Pruritus; Retrospective Studies; Risedronic Acid; Time Factors | 2008 |
Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
Topics: Adolescent; Adult; Alendronate; Autoimmune Diseases; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Bone; Glucocorticoids; Humans; Hydroxycholecalciferols; Middle Aged; Osteoporosis; Prednisolone; Premenopause; Young Adult | 2008 |
Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Collagen Type I; Crohn Disease; Dose-Response Relationship, Drug; Female; Femur Neck; Glucocorticoids; Humans; Linear Models; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Prednisolone; Steroids | 2009 |
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Drug Administration Schedule; Female; Glucocorticoids; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Parathyroid Hormone; Prednisolone; Prospective Studies; Treatment Outcome | 2010 |
Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Autoimmune Diseases; Bone Density; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Epidermolysis Bullosa Acquisita; Female; Humans; Male; Middle Aged; Osteoporosis; Pemphigoid, Benign Mucous Membrane; Pemphigoid, Bullous; Pemphigus; Prednisolone; Prospective Studies; Singapore; Skin Diseases, Vesiculobullous; Vitamin D | 2012 |
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Female; Glucocorticoids; Humans; Kidney Diseases; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prednisolone; Treatment Outcome | 2018 |
13 other study(ies) available for alendronate and prednisolone
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Prevention of corticosteroid-induced bone loss with alendronate.
Topics: Adrenal Cortex Hormones; Alendronate; Animals; Bone Density; Estradiol; Estrogens; Female; Femur; Male; Methylprednisolone; Osteocalcin; Osteoporosis; Ovariectomy; Prednisolone; Rats; Rats, Sprague-Dawley; Testosterone | 1998 |
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.
Topics: Alendronate; Animals; Apoptosis; Calcitonin; Cell Line; Cells, Cultured; Dexamethasone; Diphosphonates; Etidronic Acid; Etoposide; In Situ Nick-End Labeling; Mice; Osteoblasts; Osteocytes; Pamidronate; Prednisolone; Skull; Tumor Necrosis Factor-alpha | 1999 |
Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
Topics: Alendronate; Animals; Apoptosis; Bone Density; Bone Resorption; Cell Survival; Dexamethasone; Glucocorticoids; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteoporosis; Prednisolone | 2002 |
Modulation of bone turnover by alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs.
Topics: Absorptiometry, Photon; Adjuvants, Immunologic; Alendronate; Animals; Body Weight; Bone and Bones; Bone Density; Bone Regeneration; Bone Resorption; Femur; Glucocorticoids; Hydroxycholecalciferols; Lumbar Vertebrae; Osteoporosis; Prednisolone; Swine; Swine, Miniature; Time Factors; Tomography, X-Ray Computed | 2005 |
A case of polymyalgia rheumatica, microscopic polyangiitis, and B-cell lymphoma.
Topics: Aged; Alendronate; Antibodies, Antineutrophil Cytoplasmic; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lymphoma, B-Cell; Polymyalgia Rheumatica; Prednisolone; Vasculitis; Vincristine | 2006 |
Treatment trial of multicentric reticulohistiocytosis with a combination of predonisolone, methotrexate and alendronate.
Topics: Adult; Alendronate; Anti-Inflammatory Agents; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Methotrexate; Prednisolone | 2008 |
Metastatic malignant melanoma and dermatomyositis: A paraneoplastic phenomenon.
Topics: Adult; Alendronate; Antibodies, Antinuclear; Calcium; Dermatologic Agents; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Melanoma; Methotrexate; Paraneoplastic Syndromes; Positron-Emission Tomography; Prednisolone; Skin Neoplasms; Treatment Outcome; Vitamin D | 2011 |
Comparison of oral alendronate versus prednisolone in treatment of infants with vitamin D intoxication.
Topics: Administration, Oral; Alendronate; Anti-Inflammatory Agents; Bone Density Conservation Agents; Drug Administration Schedule; Drug Overdose; Humans; Hypercalcemia; Infant; Length of Stay; Prednisolone; Retrospective Studies; Treatment Outcome; Vitamin D | 2012 |
Practice Gaps. Improving the care of our patients who are receiving glucocorticoid therapy.
Topics: Alendronate; Anti-Inflammatory Agents; Autoimmune Diseases; Bone Density Conservation Agents; Female; Humans; Male; Osteoporosis; Prednisolone; Skin Diseases, Vesiculobullous | 2012 |
Quantitative computed tomographic assessment of bone mineral density changes associated with administration of prednisolone or prednisolone and alendronate sodium in dogs.
Topics: Administration, Oral; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Glucocorticoids; Lumbar Vertebrae; Male; Osteoporosis; Prednisolone; Tomography, X-Ray Computed | 2015 |
Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Disease Models, Animal; Glucocorticoids; Isoenzymes; Male; Osteoclasts; Osteoporosis; Phenotype; Prednisolone; Tartrate-Resistant Acid Phosphatase; Time Factors; Tissue Culture Techniques; Zebrafish; Zebrafish Proteins | 2015 |
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Glucocorticoids; Hip Fractures; Humans; Incidence; Male; Prednisolone; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk | 2017 |